Statute Details
- Title: Medicines (Licensing, Standard Provisions and Fees) Regulations
- Act Code: MA1975-RG6
- Legislation Type: Subsidiary legislation (SL)
- Authorising Act: Medicines Act (Cap. 176), Section 74
- Current Status: Current version as at 27 Mar 2026
- Citation: Rg 6; G.N. No. S 174/1987 (with later revisions/amendments)
- Key Provisions (from extract): Sections 2–6 (including standard licence provisions, grant of licences, fees, evaluation costs, and offences)
- Schedules: First Schedule (product licence standard provisions); Second Schedule (import licence standard provisions); Third Schedule (wholesale dealer’s licence); Fourth Schedule (manufacturer’s licence); Fifth Schedule (fees); Sixth Schedule (repealed)
What Is This Legislation About?
The Medicines (Licensing, Standard Provisions and Fees) Regulations (“the Regulations”) form the operational backbone for licensing activities under Singapore’s Medicines Act. In plain language, they set out (i) the standard terms that must be included in different types of licences, (ii) how licences are granted and administered by the licensing authority, (iii) the fees payable for applications and grants, and (iv) the compliance consequences for licence holders who breach the required “standard provisions”.
Rather than creating a standalone licensing regime from scratch, the Regulations work alongside the Medicines Act. The Act establishes the overall licensing framework and enforcement powers; the Regulations translate that framework into detailed, licence-specific conditions. This is particularly important for regulated entities such as product authorisation holders, importers, wholesale dealers, and manufacturers, because the standard provisions operate as mandatory contractual-like obligations imposed by law.
A notable feature of the Regulations is their tailored approach to different categories of medicines. The extract shows special standard provisions for Chinese proprietary medicines, including additional documentation and testing requirements for import and subsequent sale/supply. This reflects a risk-based regulatory approach: the licensing conditions are not one-size-fits-all, and the Regulations specify different compliance steps depending on the type of product and licence.
What Are the Key Provisions?
1. Definitions and regulatory vocabulary (Section 2)
Section 2 defines key terms used throughout the Regulations. These include: “Authority’s website” (used for official publication and notices), “licensing authority” (the Chief Executive of the Authority), and regulatory concepts such as “competent drug regulatory agency” and “reference drug regulatory agency”. The definitions also include product-change terminology such as “major variation”, which is relevant to how regulatory changes may be assessed and managed. For practitioners, these definitions matter because they determine when certain obligations are triggered and which external regulatory benchmarks may be referenced.
2. Standard provisions for licences (Section 3)
Section 3 is the core mechanism. It provides that, subject to limited exceptions, the standard provisions for licences granted under Part II of the Medicines Act are those set out in the relevant schedules: First Schedule for product licences, Second Schedule for import licences, Third Schedule for wholesale dealer’s licences, and Fourth Schedule for manufacturer’s licences.
In addition, Section 3 contains important product-specific modifications. The extract shows that for import licences relating to Chinese proprietary medicines, the standard provisions in the Second Schedule apply with specific carve-outs (e.g., excluding certain paragraphs) and with added requirements. These include: (a) a requirement for the licence holder to seek the licensing authority’s prior approval to deal with any medicinal product under the licence; (b) an obligation to provide information and documents within timeframes specified by the licensing authority; and (c) restrictions on importing, selling, or supplying unless the approval remains valid and the holder complies with applicable written law.
3. Additional post-import documentation and testing for Chinese proprietary medicines (Section 3(2)(d))
A particularly practical and compliance-heavy portion of the extract is Section 3(2)(d), which restricts sale/supply unless, within 2 months of import of the consignment, the licence holder submits specified declarations and test results. The Regulations require, among other things:
- Declarations of the absence of any poison (as defined in the Poisons Act) and any synthetic active substance in the medicinal product.
- Test results on the content of substances specified in the Medicines (Prohibition of Sale and Supply) Order (O 4).
- Microbiological testing depending on route of administration:
- Oral consumption: test results for Escherichia coli, Salmonella, Staphylococcus aureus, total yeast and mould count, and total aerobic microbial count per gram or millilitre (with an exception where the product contains active substances derived from plants/animals and produced by fermentation processes).
- External application: test results for Pseudomonas aeruginosa, Staphylococcus aureus, total yeast and mould count, and total aerobic microbial count per gram or millilitre (again with a fermentation-process exception).
- Other documents/test results as may be required by the licensing authority.
For lawyers advising importers or distributors, this is a key compliance checkpoint. It is not merely a “licence condition” in the abstract; it is a concrete submission obligation tied to timing (2 months after import) and to specific categories of microbiological contaminants. Failure to meet these requirements can expose the licence holder to enforcement action under the Regulations’ offence provisions.
4. Grant of licences and administrative control (Section 4)
Section 4 provides that every product licence, wholesale dealer’s licence, and manufacturer’s licence granted shall be subject to the standard provisions. While the extract truncates the remainder of the text, the legal effect is clear: the schedules’ standard provisions are not optional; they become part of the licence conditions. This matters in disputes because a licence holder cannot argue that a breach is “outside the licence” if the standard provisions are incorporated by law.
5. Fees and evaluation costs (Sections 5 and 5A)
Section 5 addresses fees payable in respect of applications for, and the grant of, licences and certificates, and for related administrative steps. Section 5A addresses the cost of evaluation—a mechanism commonly used in regulatory systems to recover costs associated with assessing applications, submissions, or compliance evidence. For practitioners, fee provisions are often overlooked until late-stage budgeting; however, they can materially affect timelines and cost planning for applicants.
6. Offences and enforcement (Section 6)
Section 6 provides for offences where a holder of a licence contravenes or fails to comply with any standard provision applicable to the holder. Even without the full text of Section 6 in the extract, the structure indicates that non-compliance with standard provisions is criminally or quasi-criminally actionable. From a risk-management perspective, this elevates the importance of compliance systems: standard provisions must be operationalised into SOPs, recordkeeping, and training, not merely filed as licence documents.
How Is This Legislation Structured?
The Regulations are structured as follows:
- Section 1: Citation.
- Section 2: Definitions (including regulatory and product-related terms).
- Section 3: Standard provisions for licences, including special modifications for Chinese proprietary medicines.
- Section 4: Incorporation of standard provisions into licences granted by the licensing authority.
- Section 5: Fees for applications/grants and related certificates.
- Section 5A: Cost of evaluation.
- Section 5B: Deleted (as indicated in the legislation index).
- Section 6: Offences for contravention or failure to comply with standard provisions.
- First Schedule: Standard provisions for product licences.
- Second Schedule: Standard provisions for import licences.
- Third Schedule: Standard provisions for wholesale dealer’s licences.
- Fourth Schedule: Standard provisions for manufacturer’s licences.
- Fifth Schedule: Fees.
- Sixth Schedule: Repealed.
Practically, the schedules are where most of the operational obligations live. The sections provide the “how” (incorporation, fees, offences), while the schedules provide the “what” (the actual standard provisions).
Who Does This Legislation Apply To?
The Regulations apply to entities that hold licences under Part II of the Medicines Act, specifically: product licence holders, importers (import licence holders), wholesale dealers, and manufacturers. The licensing authority is the Chief Executive of the Authority (commonly understood in practice as the Health Sciences Authority context, though the Regulations define the role rather than the institution name).
In addition, the Regulations impose special standard provisions for licences relating to Chinese proprietary medicines. Therefore, the compliance obligations of an importer or wholesale dealer may differ depending on the product category, and counsel should always verify the licence type and the product classification when advising on compliance or potential breaches.
Why Is This Legislation Important?
This Regulations is important because it converts high-level statutory licensing concepts into enforceable, standardised conditions that govern day-to-day regulated activity. For practitioners, the key legal takeaway is that standard provisions are not merely guidance—they are incorporated into licences and backed by offences for non-compliance.
From a compliance and enforcement standpoint, the Regulations’ approach has two major practical impacts:
- Predictability through standard terms: licence holders can anticipate baseline obligations through the schedules. This supports compliance planning, internal audits, and contract drafting (e.g., allocating responsibilities between importers and distributors).
- Product-specific compliance burdens: the Chinese proprietary medicine provisions illustrate how obligations can include detailed microbiological testing and declarations, with strict timing (e.g., submission within 2 months after import). These requirements can become focal points in regulatory investigations and in disputes over whether a breach occurred.
Finally, the fees and evaluation cost provisions matter for commercial planning. Regulatory submissions often involve iterative amendments, additional evidence, and administrative steps; understanding the fee and evaluation-cost framework early helps manage both cost exposure and timelines.
Related Legislation
- Medicines Act (Cap. 176), including Part II licensing framework and Section 74 authorising these Regulations
- Poison Act (Cap. 234) (relevant to declarations of absence of poison)
- Medicines (Prohibition of Sale and Supply) Order (O 4) (relevant to specified substance testing)
- Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order (O 6) (relevant definition of “Chinese proprietary medicine”)
- Medicines (Export Licence for Psychotropic Substances) Regulations (Rg 9) (relevant definition of “psychotropic substance”)
Source Documents
This article provides an overview of the Medicines (Licensing, Standard Provisions and Fees) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.